These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 2892242)
1. [Metabolic consequences of a 6-hour interruption of a continuous subcutaneous insulin infusion pump in insulin-dependent diabetic patients]. Scheen AJ Rev Med Liege; 1987 Nov; 42(21):837-52. PubMed ID: 2892242 [No Abstract] [Full Text] [Related]
2. The influence of insulin antibodies on metabolic deterioration after interruption of continuous subcutaneous insulin infusion. Montaña E; Fernández-Castañer M; Rosel P; Gómez JM; Vinzia C; Soler J Diabete Metab; 1990; 16(3):220-5. PubMed ID: 2210017 [TBL] [Abstract][Full Text] [Related]
3. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. Guerci B; Meyer L; Sallé A; Charrié A; Dousset B; Ziegler O; Drouin P J Clin Endocrinol Metab; 1999 Aug; 84(8):2673-8. PubMed ID: 10443658 [TBL] [Abstract][Full Text] [Related]
4. Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion. Scheen A; Castillo M; Jandrain B; Krzentowski G; Henrivaux P; Luyckx AS; Lefèbvre PJ Diabetes Care; 1984; 7(4):338-42. PubMed ID: 6381007 [TBL] [Abstract][Full Text] [Related]
5. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. Scheen AJ; Gillet J; Rosenthaler J; Guiot J; Henrivaux P; Jandrain B; Lefèbvre PJ Diabetologia; 1989 Nov; 32(11):801-9. PubMed ID: 2687064 [TBL] [Abstract][Full Text] [Related]
6. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin. Scheen AJ; Krzentowski G; Castillo M; Lefèbvre PJ; Luyckx AS Diabetologia; 1983 May; 24(5):319-25. PubMed ID: 6135635 [No Abstract] [Full Text] [Related]
7. Efficacy of combined insulin and somatostatin infusion for the treatment of experimental diabetic ketoacidosis. Harano Y; Ohgaku S; Hidaka H; Takatsuki K; Shigeta Y Horm Metab Res; 1979 May; 11(5):338-42. PubMed ID: 113327 [No Abstract] [Full Text] [Related]
8. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Krzentowski G; Scheen A; Castillo M; Luyckx AS; Lefèbvre PJ Diabetologia; 1983 May; 24(5):314-8. PubMed ID: 6347779 [TBL] [Abstract][Full Text] [Related]
9. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. Gerich JE; Lorenzi M; Bier DM; Schneider V; Tsalikian E; Karam JH; Forsham PH N Engl J Med; 1975 May; 292(19):985-9. PubMed ID: 804137 [TBL] [Abstract][Full Text] [Related]
10. [Lack of benefit from the intermittent administration of insulin in treatment using subcutaneous perfusion pump in type 1 diabetes]. Lilet H; Krzentowski G; Bodson A; Scheen AJ; Lefebvre PJ Diabete Metab; 1991; 17(3):363-72. PubMed ID: 1884881 [TBL] [Abstract][Full Text] [Related]
11. Role of glucagon in human diabetic ketoacidosis: studies using somatostatin. Gerich JE; Schneider VS; Lorenzi M; Tsalikian E; Karam JH; Bier DM; Forsham PH Clin Endocrinol (Oxf); 1976; 5 Suppl():299S-305S. PubMed ID: 829924 [TBL] [Abstract][Full Text] [Related]
12. Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal. Diem P; Robertson RP Br J Clin Pharmacol; 1991 Nov; 32(5):563-7. PubMed ID: 1954071 [TBL] [Abstract][Full Text] [Related]
13. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053 [TBL] [Abstract][Full Text] [Related]
14. The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level. Castillo MJ; Scheen AJ; Lefèbvre PJ J Clin Endocrinol Metab; 1996 May; 81(5):1975-8. PubMed ID: 8626867 [TBL] [Abstract][Full Text] [Related]
15. Near normalization of metabolism of IDDM: comparison of continuous subcutaneous (CSII) versus intraperitoneal (CIPII) insulin delivery. Gooch BR; Abumrad NN; Robinson RP; Crofford OB Horm Metab Res; 1984 Dec; 16 Suppl 1():190-4. PubMed ID: 6398261 [TBL] [Abstract][Full Text] [Related]
16. Lack of systematic metabolic alterations after a one-hour interruption of continuous subcutaneous insulin infusion in type I diabetic patients. Scheen A; Henrivaux P; Jandrain B; Luyckx AS; Lefebvre PJ Diabetes Care; 1985; 8(6):621-3. PubMed ID: 3908029 [No Abstract] [Full Text] [Related]
17. U-100 insulin gives some protection against metabolic deterioration due to CSII interruption. Scheen AJ; Henrivaux P; Jandrain B; Lefèbvre PJ Diabetes Care; 1987; 10(6):707-11. PubMed ID: 3322727 [TBL] [Abstract][Full Text] [Related]
18. Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients. Bruttomesso D; Fongher C; Silvestri B; Barberio S; Marescotti MC; Iori E; Valerio A; Crazzolara D; Pianta A; Tiengo A; Del Prato S Diabetes Res Clin Pract; 2001 Feb; 51(2):97-105. PubMed ID: 11165689 [TBL] [Abstract][Full Text] [Related]